BACKGROUND AND PURPOSE: To investigate whether single-fraction radiotherapy is equal to multiple fractions in the treatment of painful metastases. PATIENTS AND METHODS: The study planned to recruit 1000 patients with painful bone metastases from four Norwegian and six Swedish hospitals. Patients were randomized to single-fraction (8 Gy x 1) or multiple-fraction (3 Gy x 10) radiotherapy. The primary endpoint of the study was pain relief, with fatigue and global quality of life as the secondary endpoints. RESULTS: The data monitoring committee recommended closure of the study after 376 patients had been recruited because interim analyses indicated that, as in two other recently published trials, the treatment groups had similar outcomes. Both groups experienced similar pain relief within the first 4 months, and this was maintained throughout the 28-week follow-up. No differences were found for fatigue and global quality of life. Survival was similar in both groups, with median survival of 8-9 months. CONCLUSIONS:Single-fraction 8 Gy and multiple-fraction radiotherapy provide similar pain benefit. These results, confirming those of other studies, indicate that single-fraction 8 Gy should be standard management policy for these patients.
RCT Entities:
BACKGROUND AND PURPOSE: To investigate whether single-fraction radiotherapy is equal to multiple fractions in the treatment of painful metastases. PATIENTS AND METHODS: The study planned to recruit 1000 patients with painful bone metastases from four Norwegian and six Swedish hospitals. Patients were randomized to single-fraction (8 Gy x 1) or multiple-fraction (3 Gy x 10) radiotherapy. The primary endpoint of the study was pain relief, with fatigue and global quality of life as the secondary endpoints. RESULTS: The data monitoring committee recommended closure of the study after 376 patients had been recruited because interim analyses indicated that, as in two other recently published trials, the treatment groups had similar outcomes. Both groups experienced similar pain relief within the first 4 months, and this was maintained throughout the 28-week follow-up. No differences were found for fatigue and global quality of life. Survival was similar in both groups, with median survival of 8-9 months. CONCLUSIONS: Single-fraction 8 Gy and multiple-fraction radiotherapy provide similar pain benefit. These results, confirming those of other studies, indicate that single-fraction 8 Gy should be standard management policy for these patients.
Authors: Ya-Chen Tina Shih; Patricia A Ganz; Denise Aberle; Amy Abernethy; Justin Bekelman; Otis Brawley; James S Goodwin; Jim C Hu; Deborah Schrag; Jennifer S Temel; Lowell Schnipper Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Yoonsun Chung; Woong Sub Koom; Yong Chan Ahn; Hee-Chul Park; Hak Jae Kim; Sang Min Yoon; Sangjin Shin; Yoon Jae Lee Journal: J Cancer Res Clin Oncol Date: 2013-10-10 Impact factor: 4.553
Authors: Lucia Gutiérrez Bayard; María Del Carmen Salas Buzón; Esther Angulo Paín; Lourdes de Ingunza Barón Journal: Rep Pract Oncol Radiother Date: 2014-05-06
Authors: Sara R Alcorn; Christen R Elledge; Jean L Wright; Thomas J Smith; Todd R McNutt; Jacob Fiksel; Scott L Zeger; Theodore L DeWeese Journal: Int J Radiat Oncol Biol Phys Date: 2019-12-02 Impact factor: 7.038
Authors: N Thavarajah; L Zhang; K Wong; G Bedard; E Wong; M Tsao; C Danjoux; E Barnes; A Sahgal; K Dennis; L Holden; N Lauzon; E Chow Journal: Curr Oncol Date: 2013-10 Impact factor: 3.677
Authors: Anne M Walling; Phillip J Beron; Tania Kaprealian; Patrick A Kupelian; Neil S Wenger; Susan A McCloskey; Christopher R King; Michael Steinberg Journal: J Palliat Med Date: 2017-02-23 Impact factor: 2.947
Authors: A Gabriella Wernicke; Albert Sabbas; Fridon Kulidzhanov; Michael Shamis; Yevgeniya Golster; Ruben Niesvizky; Joseph Lane Journal: HSS J Date: 2011-12-17
Authors: A Mañas; F Casas; J P Ciria; C López; J Sáez; A Palacios; M de las Heras; C Porto; E Sánchez; C Martín; R Esco; C Veiras; J C Martínez; M Márquez; A Ramos; F Calvo; J Fuertes; F J Andreu; J Contreras; L Pérez; J Romero; J Vayreda; C Victoria Journal: Clin Transl Oncol Date: 2008-05 Impact factor: 3.405
Authors: M T King; D S J Costa; N K Aaronson; J E Brazier; D F Cella; P M Fayers; P Grimison; M Janda; G Kemmler; R Norman; A S Pickard; D Rowen; G Velikova; T A Young; R Viney Journal: Qual Life Res Date: 2016-01-20 Impact factor: 4.147